NK cells specifically TCR-dressed to kill cancer cells.

ABSTRACT:

Background

Adoptive T-cell transfer of therapeutic TCR holds great promise to specifically kill cancer cells, but relies on modifying the patient's own T cells ex vivo before injection. The manufacturing of T cells in a tailor-made setting is a long and expensive process which could be resolved by the use of universal cells. Currently, only the Natural Killer (NK) cell line NK-92 is FDA approved for universal use. In order to expand their recognition ability, they were equipped with Chimeric Antigen Receptors (CARs). However, unlike CARs, T-cell receptors (TCRs) can recognize all cellular proteins, which expand NK-92 recognition to the whole proteome.

Methods

We herein genetically engineered NK-92 to express the CD3 signaling complex, and showed that it rendered them able to

SUBMITTER: Mensali N 

PROVIDER: S-EPMC6413353 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature